vancomicina accord 1g i.v efg
accord healthcare s.l.u. - vancomicina hidrocloruro - polvo para soluciÓn inyectable - 1.000 mg - vancomicina hidrocloruro 1000 mg - vancomicina
vancomicina accord 500 mg iv efg
accord healthcare s.l.u. - vancomicina hidrocloruro - polvo para soluciÓn inyectable - 500 mg - vancomicina hidrocloruro 500 mg - vancomicina
linezolid
abaris healthcare pvt. ltd., gujarat, india. - solución para infusión intravenosa - 600 mg/ 300 ml (2 mg/ml)
linezolid
abaris healthcare pvt. ltd. - linezolid - solución para infusión iv - 200 mg/100 ml
linezolid
aishwarya healthcare. - linezolid - solución para infusión iv - 200 mg/100 ml
lucaftor ivacaptor 125 mg / lumacaftor 200 mg comprimido recubierto
gadorpharma sac - droguerÍa - comprimido recubierto - por comprimido - - lumacaftor
tigeciclina 50 mg polvo para solucion inyectable
sarmiento ccoscco agripino - droguerÍa - polvo para solucion inyectable - por vial - - tigecycline
quofenix
a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin antimoniato - infecciones adquiridas en la comunidad - antibacterianos para uso sistémico, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 y 5. se debe dar consideración a las directrices oficiales sobre el uso adecuado de agentes antibacterianos.
zinforo
pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibacterianos para uso sistémico, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.